Comments
Loading...

Bioventus Analyst Ratings

BVSNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$17.00
Lowest Price Target1
$2.50
Consensus Price Target1
$11.25

Bioventus Analyst Ratings and Price Targets | NASDAQ:BVS | Benzinga

Bioventus Inc has a consensus price target of $11.25 based on the ratings of 7 analysts. The high is $17 issued by Craig-Hallum on September 27, 2024. The low is $2.5 issued by Goldman Sachs on November 30, 2022. The 3 most-recent analyst ratings were released by Canaccord Genuity, JP Morgan, and Canaccord Genuity on March 17, 2025, December 17, 2024, and November 6, 2024, respectively. With an average price target of $14.33 between Canaccord Genuity, JP Morgan, and Canaccord Genuity, there's an implied 118.50% upside for Bioventus Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
JP Morgan
Canaccord Genuity
Craig-Hallum
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Bioventus

Buy NowGet Alert
03/17/2025Buy Now128.66%Canaccord Genuity
Caitlin Cronin38%
$15 → $15MaintainsBuyGet Alert
12/17/2024Buy Now98.17%JP Morgan
Robbie Marcus67%
$12 → $13UpgradeUnderweight → NeutralGet Alert
11/06/2024Buy Now128.66%Canaccord Genuity
William Plovanic59%
$12 → $15MaintainsBuyGet Alert
09/27/2024Buy Now159.15%Craig-Hallum
Alexander Nowak53%
$12 → $17MaintainsBuyGet Alert
08/13/2024Buy Now82.93%Canaccord Genuity
William Plovanic59%
$8 → $12MaintainsBuyGet Alert
08/07/2024Buy Now82.93%Craig-Hallum
Alexander Nowak53%
$9 → $12MaintainsBuyGet Alert
05/08/2024Buy Now21.95%Canaccord Genuity
William Plovanic59%
$7 → $8MaintainsBuyGet Alert
03/13/2024Buy Now37.2%Craig-Hallum
Alexander Nowak53%
$6 → $9MaintainsBuyGet Alert
12/07/2023Buy Now6.71%Canaccord Genuity
William Plovanic59%
$3.66 → $7UpgradeHold → BuyGet Alert
04/03/2023Buy Now-23.78%Craig-Hallum
Alexander Nowak53%
$10 → $5MaintainsHoldGet Alert
11/30/2022Buy Now-61.89%Goldman Sachs
Amit Hazan56%
$13 → $2.5MaintainsNeutralGet Alert
11/22/2022Buy NowCraig-Hallum
Alexander Nowak53%
DowngradeBuy → HoldGet Alert
11/10/2022Buy Now-23.78%Morgan Stanley
Drew Ranieri47%
$11 → $5MaintainsOverweightGet Alert
11/09/2022Buy NowCanaccord Genuity
Kyle Rose68%
DowngradeBuy → HoldGet Alert
11/09/2022Buy NowJP Morgan
Robbie Marcus67%
DowngradeOverweight → UnderweightGet Alert
10/11/2022Buy Now67.68%Morgan Stanley
Drew Ranieri47%
$12 → $11MaintainsOverweightGet Alert
09/07/2022Buy Now98.17%Goldman Sachs
Amit Hazan56%
$15 → $13MaintainsNeutralGet Alert
08/12/2022Buy Now82.93%Morgan Stanley
Drew Ranieri47%
$11 → $12MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Bioventus (BVS) stock?

A

The latest price target for Bioventus (NASDAQ:BVS) was reported by Canaccord Genuity on March 17, 2025. The analyst firm set a price target for $15.00 expecting BVS to rise to within 12 months (a possible 128.66% upside). 6 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Bioventus (BVS)?

A

The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Canaccord Genuity, and Bioventus maintained their buy rating.

Q

When was the last upgrade for Bioventus (BVS)?

A

The last upgrade for Bioventus Inc happened on December 17, 2024 when JP Morgan raised their price target to $13. JP Morgan previously had an underweight for Bioventus Inc.

Q

When was the last downgrade for Bioventus (BVS)?

A

The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.

Q

When is the next analyst rating going to be posted or updated for Bioventus (BVS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on March 17, 2025 so you should expect the next rating to be made available sometime around March 17, 2026.

Q

Is the Analyst Rating Bioventus (BVS) correct?

A

While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $15.00 to $15.00. The current price Bioventus (BVS) is trading at is $6.56, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch